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Background: Gestational diabetes mellitus (GDM) is associated with adverse pregnancy outcomes such as
preeclampsia and macrosomia. Women with polycystic ovary syndrome (PCOS) are at increased risk of developing
GDM. Today, GDM is diagnosed by oral glucose tolerance test (OGTT), a rather cumbersome test for the women
and health care system. The objectives of this study were to investigate whether HbA1c in first trimester of
pregnancy could be used as a screening test for GDM in first trimester and throughout pregnancy in order to
reduce the number of OGTTs, and whether it could predict preeclampsia and macrosomia in women with PCOS.
Methods: Post hoc analyses of data from 228 women from a prospective, randomised, multicenter study
comparing metformin to placebo from first trimester to delivery. Fasting and 2-h plasma glucose were measured
during a 75 g OGTT in first trimester, gestational week 19 and 32 as well as fasting plasma glucose in gestational
week 36. GDM was diagnosed by WHO criteria from 1999 in first trimester and throughout pregnancy and by
modified IADPSG criteria (i.e. lacking the 1-h plasma glucose value) in first trimester. The diagnostic accuracy was
assessed by logistic regression and ROC curve analysis.
Results: The area under the ROC curve for first trimester HbA1c for screening of GDM diagnosed by WHO criteria
in first trimester was 0.60 (95 % CI 0.44-0.75) and 0.56 (95 % CI 0.47-0.65) for GDM diagnosed throughout pregnancy.
Only 2.2 % (95 % CI 0.7-5.1 %) of the participants could have avoided OGTT. HbA1c was not statistically significantly
associated with GDM diagnosed by modified IADPSG criteria in first trimester. However, first trimester HbA1c was
statistically significantly associated with preeclampsia. Both HbA1c and GDM by WHO criteria in first trimester, but not
by IADPSG, were negatively associated with birth weight.
Conclusion: First trimester HbA1c can not be used to exclude or predict GDM in women with PCOS, but it might be
better to predict preeclampsia than the GDM diagnosis.
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Gestational diabetes mellitus (GDM) is defined as hyper-
glycemia first detected in pregnancy that is less severe
than diabetes mellitus in non-pregnant adults [1]. Women
with GDM are at increased risk of adverse pregnancy out-
comes, especially preeclampsia and macrosomia of the* Correspondence: ingridhov@gmail.com
1Department of Clinical Chemistry, St. Olavs Hospital, Trondheim University
Hospital, Trondheim, Norway
4Department of Cancer Research and Molecular Medicine, Faculty of
Medicine, Norwegian University of Science and Technology, Trondheim,
Norway
Full list of author information is available at the end of the article
© 2015 Odsæter et al. Open Access This art
International License (http://creativecommo
reproduction in any medium, provided you
link to the Creative Commons license, and
Dedication waiver (http://creativecommons
article, unless otherwise stated.newborn [1]. Today, several sets of diagnostic criteria exist
for GDM and a common feature is that they are based on
an oral glucose tolerance test (OGTT) [2]. These tests are
time-consuming, require overnight fasting and some
women become nauseous after drinking the glucose solu-
tion. Glycated hemoglobin A1c in blood (HbA1c), a
marker of chronic glycaemia, has been approved as a diag-
nostic test for diabetes mellitus in non-pregnant women
[3]. It has several advantages compared to OGTT, as fast-
ing, glucose ingestion and timed samples are not required,
and the preanalytical instability is less [3]. In addition, the
analysis is now well standardised [3].icle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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ing for GDM have been published [4–10], where HbA1c
typically has been measured in late second or third trimes-
ter. The results from most of the studies are consistent
with HbA1c not being a suitable screening test for GDM.
Recently, Fong et al. found that women with HbA1c of
5.7-6.4 % at first prenatal visit (up to 20 weeks of gesta-
tion) had a 3-fold higher risk of developing GDM com-
pared to those with HbA1c < 5.7 % [11]. The result
remained statistically significant when the analysis was re-
stricted to those with HbA1c measured in first trimester.
Polycystic ovary syndrome (PCOS) is characterised by
oligo-amenorrhea, hyperandrogenism and polycystic
ovaries. According to the Rotterdam criteria, at least two
of the three characteristics must be present to diagnose
the syndrome [12]. PCOS is considered to be the most
common endocrine disorder among women of fertile
age. In a Norwegian study, the prevalence of PCOS ac-
cording to the Rotterdam criteria was 14.2 % in women
with previous term deliveries [13]. In a cross-sectional
study of 392 adult Turkish women the prevalence was
19.9 % [14], and 17.8 % in a birth cohort-based study of
Australian women [15]. Women with PCOS have a
higher prevalence of impaired glucose tolerance and type
2 diabetes mellitus when compared to BMI-matched
women not having PCOS [16]. They also have an in-
creased risk of developing GDM [17–20]. A prevalence
of GDM of 25.6 % and 24.2 % by the 1999 World Health
Organization (WHO) criteria and modified (i.e. lacking
the 1-h plasma glucose value) International Association
of the Diabetes and Pregnancy Study Groups (IADPSG)
criteria, respectively, has been reported in a Norwegian
PCOS population [21]. It is widely held that in many
women GDM is an early manifestation of type 2 diabetes
mellitus, and it is suggested that women at increased
risk of diabetes should be tested for hyperglycemia early
in pregnancy [22]. As far as we know, no study on
HbA1c in pregnant women with PCOS has been pub-
lished. The primary aim of this study was to investigate
whether first trimester HbA1c in women with PCOS
could be used to screen for GDM in first trimester and
GDM diagnosed throughout pregnancy, in order to re-
duce the number of OGTTs. A secondary aim was to




The current study used data from the previously reported
PregMet (Metformin treatment in pregnant women with
PCOS) study which was a prospective, randomised,
double-blind, multicentre trial in women with PCOS com-
paring 2000 mg metformin daily against placebo from first
trimester to delivery [23]. Pregnant women with PCOSaged 18-45 years with a singleton viable fetus between
gestational week 5 and 12 were included. PCOS was di-
agnosed according to the Rotterdam criteria before the
actual pregnancy [12]. Exclusion criteria were alanine
aminotransferase > 90 IU/L, creatinine > 130 μmol/L,
known alcohol abuse, previously diagnosed diabetes
mellitus or fasting plasma or serum glucose > 7.0 mmol/L
at inclusion, treatment with oral glucocorticoids or use of
drugs known to interfere with metformin.
In the PregMet study, pregnant women were recruited
from gynaecological outpatient clinics, fertility clinics,
private practice and because of referral to an ultrasound
early in pregnancy. The participants were enrolled from
February 2005 until January 2009 at 11 study centres
(three university hospitals, seven local hospitals and one
gynaecological specialist practice) in Norway.
At inclusion, gestational week 19 and 32 a 75 g 2-h
OGTT was performed according to the recommenda-
tions of the WHO [24]. At gestational week 36, fasting
plasma or serum glucose was measured. Those already
diagnosed with GDM did not perform a new OGTT,
only fasting plasma or serum glucose was measured at
subsequent time points. All participants received written
and verbal diet recommendations according to the gen-
eral guidelines for all pregnant women in Norway. Those
diagnosed with GDM received more thorough diet and
lifestyle advice. Insulin treatment was considered if plasma
glucose levels 1–1.5 h after meal were > 8 mmol/L. Only
two of the study participants required insulin treatment.
All study participants gave a written informed consent
before inclusion. The Committee for Medical Research
Ethics of Health Region IV, Norway, and The Norwegian
Medicines Agency approved the study. The Declaration
of Helsinki was followed throughout the study and
the study was conducted according to principles of
Good Clinical Practice. The study is registered at
www.clinicaltrials.gov as NCT00159536.
Diagnostic criteria
GDM was diagnosed according to the WHO criteria
from 1999 as fasting plasma or serum glucose ≥
7.0 mmol/L or plasma or serum glucose ≥ 7.8 mmol/L
two hours after ingesting 75 g glucose orally (OGTT)
[24]. Due to the exclusion of women with fasting plasma
or serum glucose > 7 mmol/L, only participants with a
2-h OGTT result above the diagnostic cut-off value at
inclusion were diagnosed as having GDM in first trimes-
ter. In addition, participants with at least one result
above a diagnostic cut-off value at inclusion, gestational
week 19, 32 or 36 were diagnosed as having GDM through-
out pregnancy. We also diagnosed GDM in first trimester
according to modified IADPSG criteria as fasting plasma
or serum glucose ≥ 5.1 mmol/L or plasma or serum glu-
cose ≥ 8.5 mmol/L two hours after the glucose load [22].
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GDM-WHO, and participants not diagnosed with
GDM-WHO will be described as normal glucose toler-
ant (NGT-WHO). GDM diagnosed by modified IADPSG
criteria will be named GDM-IADPSG, and those not diag-
nosed with GDM-IADPSG will be called NGT-IADPSG.
Preeclampsia was diagnosed as blood pressure of 140/
90 mm Hg or higher measured on two occasions after
gestational week 20 and albuminuria of at least + 2 dip-
stick on one occasion or + 1 dipstick on two occasions.
Laboratory analyses
Plasma or serum glucose was analysed in venous blood
samples drawn from an antecubital vein between 08 and
11 am after an overnight fast. Thereafter a 75 g OGTT
was performed and two hours later a blood sample was
drawn. The samples were collected and processed in ac-
cordance with local standardised procedures at the par-
ticipating study centres.
HbA1c was not analysed during the study period. Venous
blood samples collected in EDTA tubes were stored
and available from 228 of the participants from inclu-
sion. These samples had been stored at -80 °C for four
to eight years before analysis. HbA1c is stable at these
storage conditions [25, 26]. The samples were analysed
in four runs at our hospital laboratory (St. Olavs Hos-
pital, Trondheim University Hospital) by an immuno-
turbidimetric assay on a Roche Cobas Integra 400 +
instrument (Roche Diagnostics, Mannheim, Germany)
[27]. The results are traceable to the reference method
of the International Federation of Clinical Chemistry
and Laboratory Medicine [28]. The analyses were per-
formed during a four-week period. The analytical coef-
ficient of variation from day-to-day in this period was
0.8 % at HbA1c level 5.6 % (38 mmol/mol) and 1.0 % at
HbA1c level 9.1 % (76 mmol/mol).
Statistical analyses
We used logistic regression with backwards elimination
to find the best combination of variables in predicting
GDM-WHO in first trimester, GDM-IADPSG in first tri-
mester, GDM-WHO throughout pregnancy and pre-
eclampsia. The diagnostic accuracy of the various test
combinations were assessed by receiver operating char-
acteristic (ROC) curve analysis [29]. To find the best
combination of variables predicting birth weight, we
used multiple linear regression. For all the regression
analyses we used the Royston and Altman algorithm to
find the simplest (if any) non-linear transformation of
the continuous variables [30]. The selection of variables
considered for the models was based on variables that
should be more easily available to the clinician in the
first trimester than HbA1c, and that are known to be asso-
ciated with or suspected to influence on the dependentvariable. The significance level for keeping variables in the
model was set at 0.10.
Predictor variables considered for the models for
GDM in first trimester were HbA1c, age and body mass
index (BMI) at inclusion, GDM in previous pregnancy
and using metformin at conception (i.e. using metformin
at conception and in early pregnancy followed by a
washout period of at least 7 days before inclusion in the
study). The same variables were considered for the model
predicting GDM-WHO throughout pregnancy in addition
to using metformin during pregnancy.
Predictor variables considered for the preeclampsia
model were HbA1c, age and BMI at inclusion, using
metformin at conception, using metformin during
pregnancy, GDM-WHO in first trimester, nulliparity,
smoking in first trimester (as a dichotomous variable),
preeclampsia in previous pregnancy and pre-gestational
hypertension. In addition, we performed the analyses with
GDM-IADPSG in first trimester as an independent vari-
able instead of GDM-WHO in first trimester.
The following predictor variables were considered for
the model predicting birth weight; HbA1c, age and BMI
at inclusion, using metformin at conception, using met-
formin during pregnancy, GDM-WHO in first trimester,
nulliparity and smoking in first trimester (as a dichotom-
ous variable). In addition, we performed the analyses
with GDM-IADPSG in first trimester as an independent
variable instead of GDM-WHO in first trimester.
The level of statistical significance was set at p-value
0.05. MedCalc version 12.0 for Windows (MedCalc Soft-
ware, Ostend, Belgium) was used to calculate confidence
interval for a rate. The other statistical analyses were
performed using Stata version 13.1 for Windows (Stata
Corp., Texas, USA).Results
Three hundred forty-eight women with a total of 364
pregnancies were considered eligible, whereof 90 were
excluded: 58 declined to participate and 32 did not meet
inclusion criteria. Two hundred seventy-four pregnan-
cies (in 258 women) were included. Eighteen women
were included later than intended, i.e. between gesta-
tional week 13 and 15. One woman was later excluded
due to a partial 21-hydroxylase deficiency that was ini-
tially missed. Sixteen women participated twice. In the
present post hoc analyses, we excluded the data from
the second participation from these women, to avoid de-
pendencies in the data that may bias the results. Women
with no HbA1c result at inclusion (N = 29) were also ex-
cluded. In total, 228 women were included in these post
hoc analyses, i.e. 66 % of those considered eligible. Twelve
women dropped out, eight immediately after inclusion
and four after gestational week 24. Data on pregnancy
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included in the analyses.
Population characteristics and incidence of GDM
Of the 228 included women, 55 (24.1 %) developed
GDM-WHO. Twenty women (8.8 %) had GDM-WHO
at inclusion, another 21 (9.2 %) were diagnosed in ges-
tational week 19 and 13 (5.7 %) were diagnosed in ges-
tational week 32. In addition, one (0.4 %) was diagnosed
in gestational week 36 because of an elevated fasting
plasma glucose level. Thirty-five women were diagnosed
with GDM-IADPSG at inclusion (15.4 %). Characteristics
of the study population are given in Table 1, and the
distribution of HbA1c in those with GDM-WHO and
NGT-WHO throughout pregnancy is shown in Fig. 1.
First trimester HbA1c as a screening test for GDM
HbA1c (OR 7.6 per % increase in HbA1c, 95 % CI 1.37-42,
p = 0.02) and age (OR 1.20 per year increase in age, 95 %
CI 1.07-1.35, p = 0.002) were the only significant predictor
variables in the model for GDM-WHO in first trimester,
see Table 2. The area under the ROC curve for this model
was 0.75 (95 % CI 0.63-0.88), and 0.60 (95 % CI 0.44-0.75)
for HbA1c alone. Only one woman had an HbA1c below
the cut-point that would give 100 % sensitivity (she had anTable 1 Characteristics of the study population
Characteristic N Median (min-max)
or n (%)
Age (years) 228 30 (19-44)
BMI (kg/m2) 228 27.3 (18.8-50.2)
Caucasian (no.) 228 221 (96.9 %)
GDM in previous pregnancy (no.) 228 10 (4.4 %)
Preeclampsia in previous
pregnancy (no.)
228 8 (3.5 %)
Pregestational hypertension (no.) 227 11 (4.9 %)
Smoking in first trimester (no.) 227 16 (7.1 %)
Nulliparity (no.) 228 132 (58 %)
Metformin use at conception (no.) 228 73 (32 %)
Randomised to metformin (no.) 228 114 (50 %)
Preeclampsia (no.) 228 14 (6.1 %)
Birth weight (g) 227 3550 (165-4840)
HbA1c in first trimester (%, (mmol/mol)) 228 5.1 (4.6-6.6)
(32 (27-49))
Fasting glucose in first trimester (mmol/L) 228 4.6 (3.4-6.6)
2-h glucose in first trimester (mmol/L) 226 5.4 (2.5-10.4)
Fasting glucose in gestational week 19 (mmol/L) 213 4.3 (3.4-6.6)
2-h glucose in gestational week 19 (mmol/L) 198 5.7 (2.4-10.7)
Fasting glucose in gestational week 32 (mmol/L) 202 4.4 (3.1-9.4)
2-h glucose in gestational week 32 (mmol/L) 177 6.2 (2.5-9.8)
Fasting glucose in gestational week 36 (mmol/L) 194 4.3 (3.4-9.2)HbA1c of 4.6 % (27 mmol/mol)), and only four women
had an HbA1c above the cut-off level giving 100 % specifi-
city (i.e. HbA1c > 5.6 % (38 mmol/mol)), see Table 3.
Therefore, only five of the 228 patients (2.2 %, 95 % CI
0.7-5.1 %) could have avoided an OGTT if we had used
these cut-off levels.
Only higher age was associated with GDM-IADPSG in
first trimester (OR 1.10 per year increase in age, 95 % CI
1.01-1.19, p = 0.03), see Table 2.
Predictor variables included in the model for GDM-
WHO throughout pregnancy were HbA1c at inclusion
(OR 3.1 per % increase in HbA1c, 95 % CI 0.87-11, p =
0.08), GDM in previous pregnancy (OR 3.2, 95 % CI
0.85-12, p = 0.08) and age (OR 1.10 per year increase in
age, 95 % CI 1.02-1.18, p = 0.01), see Table 2. The area
under the ROC curve of this combination of variables in
diagnosing GDM-WHO throughout pregnancy was 0.65
(95 % CI 0.56-0.73), while with HbA1c as the only dis-
criminator the area under the ROC curve was 0.56
(95 % CI 0.47-0.65). The same five participants as men-
tioned in the previous section on GDM diagnosed in
first trimester only, could have avoided an OGTT by
screening with HbA1c in first trimester for GDM-WHO
throughout pregnancy if we had required 100 % sensitiv-
ity and 100 % specificity to exclude and to predict GDM,
respectively, see Table 3.
We did not find any non-linear association between
the possible continuous predictor variables and the out-
come variables.
First trimester HbA1c as a predictor for preeclampsia and
birth weight
Variables included in the model predicting preeclampsia
were HbA1c at inclusion (OR 17 per % increase in
HbA1c, 95 % CI 2.4-115, p = 0.004), preeclampsia in pre-
vious pregnancy (OR 27, 95 % CI 2.0-353, p = 0.01) and
nulliparity (OR 7.7, 95 % CI 0.97-62, p = 0.054), see
Table 2. The area under the ROC curve of this combin-
ation of variables in diagnosing preeclampsia was 0.79
(95 % CI 0.67-0.90), and 0.65 (95 % CI 0.48-0.82) for
HbA1c alone. Six participants had HbA1c of 4.7 %
(28 mmol/mol) or less and none of them had pre-
eclampsia (this was the highest cut-off level giving 100 %
sensitivity). Two participants had values higher than
5.7 % (39 mmol/mol), and both had preeclampsia (this
was the lowest value giving 100 % specificity). Using
these cut-off levels could have made us predict or ex-
clude preeclampsia in eight of 228 women (3.5 %, 95 %
CI 1.5-6.9 %). Neither GDM-WHO nor GDM-IADPSG
diagnosed in first trimester was statistically significantly
associated with preeclampsia.
Variables included in the model for birth weight were
GDM-WHO in first trimester (β -311 g, 95 % CI -608 to

































Fig. 1 The distribution of HbA1c in those diagnosed with gestational diabetes mellitus and not (throughout pregnancy) by the 1999 WHO
criteria. In addition to the histograms, the figure shows a kernel density plot of HbA1c in each group, where the distributions are smoothed and
scaled to the same level of probability density
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95 % CI -381 to -41, p = 0.02), see Table 4. When substi-
tuting GDM-WHO in first trimester with GDM-IADPSG
in first trimester the following variables were included in
the model; HbA1c in first trimester (β -318 g per % in-
crease in HbA1c, 95 % CI -660 to 25, p = 0.07), using met-
formin at conception (β 245 g, 95 % CI 66-423, p = 0.007)
and nulliparity (β -193 g, 95 % CI -362 to -24, p = 0.03).
We did not find any non-linear association between
the possible continuous predictor variables and the out-
come variables.
Discussion
HbA1c in first trimester could not discriminate well be-
tween GDM-WHO and NGT-WHO throughout preg-
nancy in PCOS women; only 2.2 % could have avoided
an OGTT if we had required 100 % sensitivity and
100 % specificity to exclude and to predict GDM, respect-
ively. When lowering the cut-offs to 96 % sensitivity and
94 % specificity, 15.8 % could have avoided an OGTT.Table 2 Odds ratio, 95 % confidence interval and p-value for predic





Predictor OR 95 % CI p-value OR 95
HbA1c 7.6 1.37-42 0.02
Age 1.20 1.07-1.35 0.002 1.10 1.
GDM in previous pregnancy
Preeclampsia in previous pregnancy
Nulliparity
aModified IADPSG criteria were used, i.e. the 1-h plasma glucose value was missingHowever, more than one third of those avoiding an OGTT
would be incorrectly classified. This was also true for
GDM-WHO and GDM diagnosed by modified IADPSG
criteria in first trimester only. However, first trimester
HbA1c was statistically significantly associated with pre-
eclampsia, a complication that the GDM diagnosis is sup-
posed to predict, but could not predict in this study.
To our knowledge, this is the first study on HbA1c as
a screening test for GDM in pregnant women with
PCOS, who have a significantly increased risk of GDM,
compared to an average pregnant population [17–20].
Several studies have indicated that HbA1c is not a suit-
able screening test for GDM, but most of them have mea-
sured HbA1c in late second or third trimester [4–8, 10].
Maegawa et al. evaluated HbA1c in first trimester as a
screening test for GDM [9]. The population consisted of
pregnant women in Japan. They used the GDM criteria of
the Japan Society of Obstetrics and Gynecology and the
Japan Diabetes Society, where two or more of the follow-






% CI p-value OR 95 % CI p-value OR 95 % CI p-value
3.1 0.87-11 0.08 17 2.4-115 0.004




Table 3 Performance parameters for first trimester HbA1c in screening for gestational diabetes mellitus diagnosed by 1999 WHO
criteria in first trimester and throughout pregnancy
Diagnosis Cut-off level for HbA1c for
dropping OGTT, % (mmol/mol)
Sensitivity, % Specificity, % Number of women
avoiding OGTT
Number of women avoiding
OGTT incorrectly classified
GDM-WHO in first trimester <4.7 (28) 100 0.5 1 0
<4.8 (29) 95.0 2.4 6 1
<4.9 (30) 95.0 7.8 17 1
>5.4 (36) 30.0 93.7 19 13
>5.5 (37) 25.0 97.6 10 5
>5.6 (38) 20.0 100 4 0
GDM-WHO throughout pregnancy <4.7 (28) 100 0.6 1 0
<4.8 (29) 98.2 2.9 6 1
<4.9 (30) 96.4 8.7 17 2
>5.4 (36) 14.6 93.6 19 11
>5.5 (37) 9.1 97.1 10 5
>5.6 (38) 7.3 100 4 0
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10.0 mmol/L and 2-h glucose after 75-g OGTT ≥
8.3 mmol/L [9]. Their conclusion, that first trimester
HbA1c was not suitable as a screening test for GDM diag-
nosed by glucose-based criteria, is in line with our present
observation in PCOS women. Further, Hughes et al. found
an area under the ROC curve for first trimester HbA1c in
detecting GDM diagnosed by IADPSG OGTT criteria
before gestational week 20 of only 0.711 [31]. An HbA1c <
4.8 % (29 mmol/mol) excluded GDM, however, the specifi-
city was only 3.0 %. The study took place in a primary care
setting in a population with a relatively low risk of GDM.
WHO states that women with hyperglycemia detected
in pregnancy are at increased risk of adverse pregnancy
outcomes, especially preeclampsia and macrosomia, and
that treating GDM is effective in reducing adverse preg-
nancy outcomes [1]. In other words, a major goal in
diagnosing GDM is to identify those at risk of pregnancy
complications. According to our results, GDM-WHO in
first trimester and HbA1c in first trimester were both
negatively associated with birth weight, while the GDM-
IADPSG diagnosis in first trimester was not associated
with birth weight. It is noteworthy that the associations
were in the opposite direction from what we expected,
i.e. higher HbA1c and GDM-WHO in first trimester
were associated with lower birth weight. Further, we foundTable 4 Regression coefficients, 95 % confidence intervals and p-va
Predictor Model 1
β 95 % CI
GDM-WHO in first trimester -311 -608 to -14
Using metformin at conception 255 75-436
Nulliparity -211 -381 to -41
HbA1cthat HbA1c in first trimester was significantly associated
with preeclampsia, while the GDM-WHO and the GDM-
IADPSG diagnoses in first trimester were not. The OR for
preeclampsia per % increase in HbA1c was as high as 17,
but due to a relatively low number of study participants
the uncertainty of the estimate was large (95 % CI 2.4-
115). The HAPO (Hyperglycemia and Adverse Pregnancy
Outcome) study concluded that for plasma glucose and
HbA1c the ORs were similar for primary cesarean section,
preeclampsia and preterm delivery [32]. These results are
not in line with the present study, but in the HAPO study,
glucose and HbA1c were measured during gestational
week 24-32, which may explain some of the discrepancy.
Another possible explanation is that we studied only preg-
nant women with PCOS. One study examining whether
first trimester HbA1c could detect women at increased
risk of preeclampsia, was the previously mentioned study
by Hughes et al [31]. They found that the relative risk for
preeclampsia was 2.42 (95 % CI 1.34-4.38) for women with
a first trimester HbA1c of 5.9-6.4 % (41-46 mmol/mol)
compared to those with HbA1c < 5.9 %. However, no re-
sults on first trimester plasma glucose or GDM in predict-
ing preeclampsia were reported, so we cannot compare
HbA1c to any of those.
In several of the diagnostic criteria for GDM used
today, including the WHO and IADPSG criteria, onlylues for two models predicting birth weight (in grams)
Model 2
p-value β 95 % CI p-value
0.04
0.006 245 66-423 0.007
0.02 -193 -362 to -24 0.03
-318 -660 to 25 0.07
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is required to diagnose GDM [2]. The reproducibility of
OGTT in pregnancy, measured with 1-2 weeks gap, has
been reported to be poor; 22-24 % of the participants
were reclassified [33, 34]. Considering the results of
Hughes et al. [31] (i.e. that HbA1c identifies women at
increased risk of preeclampsia) and ours (i.e. that HbA1c
might be a better predictor for preeclampsia than GDM
diagnosis), the poor reproducibility of OGTT in preg-
nancy and advantages of HbA1c compared to OGTT (as
fasting, glucose ingestion and timed samples is not re-
quired, and that the preanalytical instability is less), we
suggest that HbA1c in first trimester should be further
evaluated as a possible risk marker for preeclampsia and
compared to GDM diagnosed by established criteria in
larger, prospective studies in various populations.
Women with fasting plasma or serum glucose >
7.0 mmol/L at time of inclusion were not included in
the study, so our results are not representative for that
group of women. However, only one of the 348 women
considered eligible for inclusion was not included due to
a fasting plasma glucose >7.0 mmol/L. Further, only one
woman had a plasma glucose result at the time she was
diagnosed with GDM-WHO above the diagnostic thresh-
old for diabetes mellitus in non-pregnant women [24]. She
had elevated fasting plasma glucose in gestational week
36. Our results are not representative for pregnant women
with glucose values consistent with diabetes mellitus in
non-pregnant adults. In the study by Hughes et al. the
area under the ROC curve for first trimester HbA1c in de-
tecting diabetes diagnosed by WHO OGTT criteria before
20 weeks gestation was 0.991, with a sensitivity of 100 %
and specificity of 97.4 % at the optimal cut-off point of
5.9 % (41 mmol/mol) [31]. Accordingly, one could expect
that first trimester HbA1c performs better as a screening
test for higher degrees of glycemia than in our study, also
in pregnant women with PCOS.
About one third of the women in the present study
used metformin at conception and in early pregnancy,
followed by a washout period of at least 7 days before in-
clusion in the study (Table 1). Further, half of the partici-
pants were randomised to metformin from first trimester
to delivery (Table 1). Seventy-nine women (35 %) did not
use metformin at any time point during pregnancy. GDM
prevalence and main characteristics by metformin use and
GDM status can be found in Additional file 1. As metfor-
min is an antidiabetic drug, one could suspect that the use
of metformin might have influenced our results. Cur-
rently, the only randomised controlled trial on women
with PCOS on metformin versus placebo from first tri-
mester to delivery with GDM as one of the outcome mea-
sures is the PregMet study, which the present results are
from. In the PregMet study, metformin did not demon-
strate an effect on the prevalence of GDM [35]. Further, inthe pilot study to the PregMet study, no effect of metfor-
min on indices of glucose homeostasis in women with
PCOS was found [36]. However, this does not exclude that
metformin has an effect during pregnancy, and especially,
it says nothing about the effect of metformin at concep-
tion and early in pregnancy. Because of this, randomisa-
tion was considered as an independent variable in the
models predicting GDM throughout pregnancy, pre-
eclampsia and birth weight. Using metformin after ran-
domisation did not reach the significance level required to
be included in a model (p ≤ 0.10) for any of the models.
Further, using metformin at conception and in early preg-
nancy was also considered as an independent variable for
all the models in the present study, in order to adjust for
possible confounding. It only reached the significance
level required to be included in a model (p ≤ 0.10) for the
models predicting birth weight.
Those diagnosed with GDM-WHO in the present
study received more thorough diet and lifestyle advice
compared to those with NGT-WHO, and two were
treated with insulin, and could thereby have prevented
adverse outcomes. By this, it is possible that the associa-
tions between the predictor variables and the adverse
pregnancy outcomes are underestimated. Further, we
were only able to evaluate HbA1c as a screening test re-
lated to modified IADPSG criteria as 1-h glucose values
from OGTT were not available. Studies using modified
IADPSG criteria have already been published [37, 38].
The proportion of GDM cases diagnosed by 1-h value
only when using the IADPSG criteria, has been esti-
mated to 14-21 % [39–41]. According to this, we might
have lost up to one fifth of GDM-IADPSG cases, and
this must be kept in mind when interpreting the results.
In addition, we could evaluate HbA1c as a screening test
for GDM diagnosed by the modified IADPSG criteria in
first trimester only, and not later in pregnancy. The rea-
son for this was that those with a GDM diagnosis by the
WHO criteria did not perform an OGTT at later time
points, i.e. only those not diagnosed with GDM-WHO
performed OGTT at later time points. As an example if
a woman got GDM by WHO criteria because of a 2-h
serum glucose value of 8.0 mmol/L and fasting plasma
glucose of 5.0 mmol/L, she would not get the diagnosis
by IADPSG criteria, and we would not know if she would
have developed GDM by IADPSG criteria at a later time
point. Accordingly, we cannot tell whether first trimester
HbA1c could be a potential screening test for GDM diag-
nosed by IADPSG criteria later in pregnancy.
Conclusion
In women with PCOS, first trimester HbA1c is not a
good screening test for GDM in the first trimester or
later in pregnancy; however, it might be better than the
GDM diagnosis in predicting preeclampsia.
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